• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Natera Inc.

    1/2/26 4:13:25 PM ET
    $NTRA
    Medical Specialities
    Health Care
    Get the next $NTRA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0002010019
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    NATERA, INC.
    SEC File Number
    001-37478
    Address of Issuer
    13011 McCallen Pass
    Building A Suite 100
    Austin
    TEXAS
    78753
    Phone
    (650) 980-9190
    Name of Person for Whose Account the Securities are To Be Sold
    SOLOMON MOSHKEVICH
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    2951675621.4213801446501/02/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common10/26/2025Restricted StockISSUERCheckbox not checked95110/26/2025Not Applicable
    Common10/27/2025Restricted StockISSUERCheckbox not checked113010/27/2025Not Applicable
    Common07/27/2025Restricted StockISSUERCheckbox not checked59107/27/2025Not Applicable
    Common10/20/2025Restricted StockISSUERCheckbox not checked27910/20/2025Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    SOLOMON MOSHKEVICH
    13011 McCallen Pass
    Building A Suite 100
    Austin � TX � 78753
    Common12/12/202546921082714.19
    SOLOMON MOSHKEVICH
    13011 McCallen Pass
    Building A Suite 100
    Austin � TX � 78753
    Common12/01/20253000714458.70
    SOLOMON MOSHKEVICH
    13011 McCallen Pass
    Building A Suite 100
    Austin � TX � 78753
    Common11/03/20253000595809.91
    SOLOMON MOSHKEVICH
    13011 McCallen Pass
    Building A Suite 100
    Austin � TX � 78753
    common10/28/20251198229371.36
    SOLOMON MOSHKEVICH
    13011 McCallen Pass
    Building A Suite 100
    Austin � TX � 78753
    common10/27/20251008193862.59
    SOLOMON MOSHKEVICH
    13011 McCallen Pass
    Building A Suite 100
    Austin � TX � 78753
    common10/21/202529254881.40

    144: Remarks and Signature

    Remarks
    Date of Notice
    01/02/2026
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/26/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Solomon Moshkevich

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $NTRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTRA

    DatePrice TargetRatingAnalyst
    1/7/2026$300.00Buy
    Citigroup
    12/2/2025$265.00Overweight
    Morgan Stanley
    10/27/2025$172.00Underperform → Neutral
    BNP Paribas Exane
    9/22/2025$175.00Equal Weight
    Wells Fargo
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    1/23/2025$200.00Overweight
    Barclays
    6/3/2024$142.00Buy
    Jefferies
    4/8/2024$117.00Buy
    Craig Hallum
    More analyst ratings

    $NTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $675,621 worth of shares (2,951 units at $228.95), decreasing direct ownership by 2% to 123,499 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    1/6/26 9:05:09 PM ET
    $NTRA
    Medical Specialities
    Health Care

    CO-FOUNDER Sheena Jonathan exercised 39,615 shares at a strike of $9.59, increasing direct ownership by 18% to 262,581 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    1/6/26 9:05:11 PM ET
    $NTRA
    Medical Specialities
    Health Care

    CEO AND PRESIDENT Chapman Steven Leonard sold $881,482 worth of shares (3,848 units at $229.08), decreasing direct ownership by 3% to 136,568 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    1/6/26 9:05:06 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth

    2025 revenues are expected to increase by approximately 35% compared to 2024, which is approximately $40 million above the top end of Natera's financial outlook Additional business updates will be presented at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today released preliminary unaudited results for the fourth quarter and full year ended December 31, 2025. The Company expects the following: Total revenues of approximately $660 million in the fourth quarter of 2025 compared to $476 million in the fourth quarter of 2024, an increase of approximately 39%. Total revenues, excl

    1/11/26 10:48:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial

    Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson's disease and other neurodegenerative diseases today announced the appointment of Kirk Stockwood as Senior Vice President, Commercial. Mr. Stockwood will spearhead Octave's commercial strategy as the company scales operations and expands the reach of its precision neurology platform. Mr. Stockwood brings over 20 years of leadership experience in specialty diagnostics and tools, with a proven track record of commercial scaling within public and private companies. Most recently as Vice President of Sales at Quanterix, he led a global team focused on

    1/8/26 4:01:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

    – STELLAR-316 will use Natera's Signatera™ assay to identify MRD-positive patients for trial enrollment and to monitor response to therapy – Exelixis, Inc. (NASDAQ:EXEL) and Natera (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 pivotal trial will evaluate zanzalintinib, Exelixis' novel oral kinase inhibitor, with and without an immune checkpoint inhibitor, in patients with resected stage II/III colorectal cancer (CRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107329077/en/ Using Nat

    1/7/26 8:00:00 AM ET
    $EXEL
    $NTRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    $NTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Natera with a new price target

    Citigroup initiated coverage of Natera with a rating of Buy and set a new price target of $300.00

    1/7/26 9:12:45 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Morgan Stanley resumed coverage on Natera with a new price target

    Morgan Stanley resumed coverage of Natera with a rating of Overweight and set a new price target of $265.00

    12/2/25 8:28:19 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Natera from Underperform to Neutral and set a new price target of $172.00

    10/27/25 9:03:32 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    SEC Filings

    View All

    SEC Form 144 filed by Natera Inc.

    144 - Natera, Inc. (0001604821) (Subject)

    1/2/26 4:13:25 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form 144 filed by Natera Inc.

    144 - Natera, Inc. (0001604821) (Subject)

    12/12/25 10:07:26 AM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form S-3ASR filed by Natera Inc.

    S-3ASR - Natera, Inc. (0001604821) (Filer)

    12/10/25 9:02:55 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Natera Inc.

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    11/14/24 4:02:50 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    6/7/24 12:07:25 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    2/14/24 4:06:56 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Leadership Updates

    Live Leadership Updates

    View All

    Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial

    Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson's disease and other neurodegenerative diseases today announced the appointment of Kirk Stockwood as Senior Vice President, Commercial. Mr. Stockwood will spearhead Octave's commercial strategy as the company scales operations and expands the reach of its precision neurology platform. Mr. Stockwood brings over 20 years of leadership experience in specialty diagnostics and tools, with a proven track record of commercial scaling within public and private companies. Most recently as Vice President of Sales at Quanterix, he led a global team focused on

    1/8/26 4:01:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer

    Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

    6/5/23 11:06:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

    Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations

    2/23/23 8:05:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Financials

    Live finance-specific insights

    View All

    Natera Acquires Foresight Diagnostics

    Expands Natera's lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm1 Cutting-edge IP adds to Natera's portfolio of >500 issued or pending patents Accelerates Natera's expansion into lymphoma, where Foresight has developed a strong clinical position Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire Foresight. Foresight is a cancer diagnostics company and CLIA-registered laboratory. The company's ci

    12/5/25 7:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Reports Third Quarter 2025 Financial Results

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025. Recent Financial Highlights Generated total revenues of $592.2 million in the third quarter of 2025, compared to $439.8 million in the third quarter of 2024, an increase of 34.7%. Product revenues grew 35.3% over the same period. Generated a gross margin percentage2 of 64.9% in the third quarter of 2025, compared to a gross margin percentage2 of 61.8% in the third quarter of 2024. Processed approximately 893,600 tests in the third quarter of 2025, compared to approximately 775,800 tests in the third quarter of 2024,

    11/6/25 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera to Report its Third Quarter Results on November 6, 2025

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2025, after the market closes on November 6, 2025. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET. Earnings Conference Call Information Event: Natera's Third Quarter 2025 Financial Results Date: November 6, 2025 Time: 4:30 p.m. ET Live Dial-In: 1-888-770-7321 (Domestic)   1-929-201-7107 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/822764987

    10/30/25 7:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care